Selecta Biosciences, Inc. (SELB) Q4 2019 Earnings Conference Call March 12, 2020 8:30 AM ET Company Participants Elona Kogan - General Counsel Carsten Brunn - President and Chief Executive Officer Brad Dahms - Chief Financial Officer Kei Kishimoto - Chief Scientific Officer Conference Call Participants Ellie Merle - Cantor Fitzgerald Raju Prasad - William Blair Chad Messer - Needham & Company John Newman - Canaccord Yun Zhong - Janney Difei Yang - Mizuho Securities USA Operator Good morning and welcome to ...

O ရှိ Selecta.. Biosciences Corporate Presentation February 2020 Nasdaq SELB Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate sup ...

O श्रे Selecta… Biosciences Corporate Presentation January 2020 SELB Nasdaq Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate supe ...

O ato Selecta… Biosciences Corporate Presentation November 2019 SELB Nasdaq Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate supe ...

Selecta Biosciences, Inc. (SELB) Q3 2019 Results Earnings Conference Call November 8, 2019 8:30 AM ET Company Participants Elona Kogan - Corporate Secretary, General Counsel Carsten Brunn - President, Chief Executive Officer Alison Schecter - Chief Medical Officer Brad Dahms - Chief Financial Officer Conference Call Participants Chad Messer - Needham & Company Bill Grau - Stifel Chris French - Canaccord Alex Lim - Mizuho Yun Zhong - Janney Operator Good morning and welcome to the Selecta Biosciences' third ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (I.R.S. Employer Identification No.) (State or other jurisdic ...

O ato Selecta. Biosciences Corporate Presentation October 2019 Nasdaq SELB Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate super ...

Financial Data and Key Metrics Changes - Revenue recognized for Q2 2019 was less than $0.1 million under the collaboration agreement with Spark, compared to no revenue recognized in Q2 2018 [30] - R&D expenses for Q2 2019 were $12.1 million, down from $14.4 million in Q2 2018, primarily due to reduced salaries and benefits from headcount reduction [31] - G&A expenses for Q2 2019 were $4.1 million, compared to $4.4 million in Q2 2018, mainly due to reduced legal fees [32] - The net loss for Q2 2019 was $16.4 million or $0.37 per share, compared to a net loss of $18.8 million or $0.84 per share in the same period of 2018 [32] - As of June 30, 2019, the company had $42 million in cash and equivalents, down from $48.7 million as of March 31, 2019 [33] Business Line Data and Key Metrics Changes - The lead development program, SEL-212, for chronic refractory gout is progressing with patient enrollment ongoing in the COMPARE trial [10] - Data from the completed Phase II trial of SEL-212 showed that 66% of evaluable patients maintained serum uric acid levels below six milligrams per deciliter after five monthly treatments [21] - The market potential for chronic refractory gout is estimated at over $1 billion, with approximately 160,000 patients in the U.S. [28] Market Data and Key Metrics Changes - The company is focusing on partnerships for its ImmTOR platform to enhance gene therapy solutions targeting systemic diseases [15] - The collaboration with AskBio aims to develop a broad portfolio of AAV gene therapies, leveraging AskBio's proven track record in gene therapy [11] Company Strategy and Development Direction - The company is excited about the potential of its ImmTOR platform in therapeutic biologics, enzymes, and AAV gene therapy [8] - Strategic partnerships are seen as essential for realizing the vision for gene therapy, particularly with the recent partnership with AskBio [15] - The company plans to continue advancing its AAV gene therapy program and is focused on building its team to support these initiatives [17] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the late-stage asset for chronic refractory gout and looks forward to announcing interim data from the COMPARE trial in Q4 2019 [35] - The company believes its platform has broad potential and is eager to unlock value through partnerships, particularly with AskBio [35] Other Important Information - The company welcomed Dr. Alison Schecter as Chief Medical Officer, bringing extensive experience in drug development [16] - The company has two internal gene therapy programs, MMA and OTC, which are planned to be integrated into the partnership with AskBio [56] Q&A Session Summary Question: Impact of partnership with AskBio on financial situation - Management indicated that the partnership will have little impact on financials in 2019 and does not limit future partnerships [39] Question: Update from Spark about opting in - Management confirmed ongoing communication with Spark regarding their opportunity to opt into additional indications [45] Question: Plans for Phase III/IV of SEL-212 - Management stated that plans for Phase III are still in place, dependent on funding availability [49] Question: Interim readout patient data expectations - Management committed to an interim readout towards the end of the year but did not specify patient data range [50] Question: Development programs with AskBio - Management confirmed plans for additional development programs with AskBio beyond the MMA program [63]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (State or other jurisdiction of incorporation or organization) (I. ...

Selecta Biosciences, Inc. (SELB) Q1 2019 Results Conference Call May 9, 2019 8:30 AM ET Company Participants Elona Kogan - General Counsel & Corporate Secretary Carsten Brunn - CEO Stephen Smolinski - CCO Conference Call Participants Difei Yang - Mizuho Securities Derek Archila - Stifel Operator Thank you for holding. Welcome to the Selecta Biosciences First Quarter Financial Results Conference Call. [Operator Instructions] This call is being webcast live on the Investors and Media section of Selecta's webs ...